This investigation determined if 3 levels of controlled caffeine consumption affected fl uid-electrolyte balance and renal function differently. Healthy males (mean ± standard deviation; age, 21.6 ± 3.3 y) consumed 3 mg caffeine · kg
This investigation determined if 3 levels of controlled caffeine consumption affected fl uid-electrolyte balance and renal function differently. Healthy males (mean ± standard deviation; age, 21.6 ± 3.3 y) consumed 3 mg caffeine · kg -1 · d -1 on days 1 to 6 (equilibration phase). On days 7 to 11 (treatment phase), subjects consumed either 0 mg (C0; placebo; n = 20), 3 mg (C3; n = 20), or 6 mg (C6; n = 19) caffeine · kg -1 · d -1 in capsules, with no other dietary caffeine intake. The following variables were unaffected (P > 0.05) by different caffeine doses on days 1, 3, 6, 9, and 11 and were within normal clinical ranges: body mass, urine osmolality, urine specifi c gravity, urine color, 24-h urine volume, 24-h Na + and K + excretion, 24-h creatinine, blood urea nitrogen, serum Na + and K + , serum osmolality, hematocrit, and total plasma protein. Therefore, C0, C3, and C6 exhibited no evidence of hypohydration. These fi ndings question the widely accepted notion that caffeine consumption acts chronically as a diuretic.
The purported diuretic effects of methylxanthines (i.e., caffeine in coffee, tea, and soft drinks; theophylline in tea; and theobromine in tea, chocolate, and cocoa) have been recognized for more than 75 y (14) , yet the complex evidence regarding fl uid and electrolyte homeostasis is presently diffi cult to interpret for the following reasons. First, the fact that diuretics and dehydration degrade exercise performance (3) has prompted dieticians, clinicians, and exercise physiologists to denounce the use of caffeine in books (8, 21, 37) and government reports (22) . In support of these admonitions, 2 laboratory studies detected an acute diuretic effect of caffeine (versus placebo) when urine was collected for 2 to 4 h (17, 31) after ingestion of 250 and 360 mg caffeine, respectively. The latter study (31) involved 1 caveat, however: the acute urine production associated with low oral doses of caffeine (45, 90, and 180 mg) was not different from placebo. This suggested that regulation of total body water could be affected only above a certain caffeine ingestion threshold (i.e., between 180 and 360 mg). Similarly, reviews of the scientifi c literature (2, 25) have concluded that caffeine does not induce chronic hypohydration when consumed in moderation, but might have a diuretic effect at greater dosages [(i.e., > 250 mg/d, (27) ; > 680 mg/d (2)]. Second, controlled caffeine intakes ranging from 114 to 458 mg (1.4 to 6.0 mg/kg) stimulated no acute diuretic response in 1.3 to 4.0 h, when compared to a placebo (10, 19, 23) . These 3 studies suggested that caffeine does not alter fl uid-electrolyte balance chronically. Third, only one of the above studies collected urine for 24 h (19), with an adequate subject sample size. Also, previous research has shown that acute urine samples (≤ 24 h) collected during rest cannot be projected to chronic fl uid-electrolyte balance across several days or during exercise (7, 36) .
Because chronic hypohydration and electrolyte depletion could negatively infl uence exercise performance (11, 34) and health (1), our research team previously published a fi eld study (15) that observed ten young athletes during three consecutive days of recreational activities (4h/d). Subjects drank only water during training sessions, but rehydrated with one of two beverage conditions, providing either 245 mg (calculated group mean, 3.6 mg/kg) or 0 mg caffeine. No signifi cant differences were detected between the caffeinated and noncaffeinated beverages for urine volume, percentage of ingested fl uid that was retained, body mass, circulatory indices, and urinary markers of hydration.
The present investigation represents our second systematic assessment of potential chronic hypohydration, while consuming moderate levels of dietary caffeine. This investigation measured fl uid-electrolyte turnover and indices of hydration in active young men, during 11 d of controlled dietary caffeine intake. Subjects were randomly divided into three treatment groups that consumed either 0, 3, or 6 mg caffeine · kg -1 · 24 h -1 via capsules, for 5 d. Based on the lack of supporting research in the nutrition literature, we hypothesized that no between-group differences would occur for any of the 20 variables that assessed whole-body hydration.
Methods
Fifty-nine healthy males, age 18 to 34 y, participated in this investigation. Exclusionary factors included tobacco smoking, body mass outside the range 60 to 85 kg, varsity athlete status, participation in prolonged or intense exercise, exercise less than twice per week, lactose intolerance, and consuming more than 8 cola bever-ages or 4 cups (150 mL) of brewed coffee per day. Subjects completed a medical history questionnaire to verify that they were healthy, not taking medications that affect caffeine metabolism or the physiological variables measured, and were free from cardiovascular, metabolic, or respiratory disease. The local institutional review board for human studies approved this protocol and each subject provided written, informed consent to participate.
Preliminary Visit
Subjects visited the University of Connecticut Human Performance Laboratory 2 to 4 d prior to any experimental data collection to receive information pertaining to the study diet and collection of 24-h urine samples. Height was measured to the nearest 1 cm, and body mass was measured on a platform scale (± 100 g; model DS44L, Ohaus Corp., Florham Park, NJ). Body-mass index (BMI) was calculated from the foregoing measurements, using the following formula: BMI = body mass/(height 2 ). An activity questionnaire was administered to evaluate the duration, type, and frequency of exercise during the 30 d prior to data collection. Subjects were instructed to maintain their usual exercise program throughout this investigation.
Subjects met with a registered dietitian (RD) to learn proper food/fl uid recording procedures and receive a packet of dietary records for days -2 to 11; this packet included two educational handouts to help subjects estimate food portion sizes. The RD instructed subjects to abstain from caffeinated foods and beverages, to maintain their normal exercise program, and not to begin taking new nutritional supplements beginning 48 h prior to day 1. Participants also received a list of the foods, beverages, and medications that they should avoid including items that contained caffeine, had diuretic properties, or affected caffeine metabolism (i.e., cruciferous vegetables, char-broiled meats).
Caffeine consumption prior to the study was determined from a caffeine and tobacco use questionnaire (Harris Lieberman, personal communication). Average caffeine consumption in mg was calculated using the table formulated by Harland (20) . The RD met with subjects each morning (days 1 to 11) to optimize completeness and accuracy of food and fl uid records. Dietary components were analyzed with commercial software (Nutritionist Pro, version 1.2, N-Squared Computing, Salem, OR) which computed carbohydrate, fat, and protein (percent); caloric intake (kcal); and sodium and potassium (total mEq). The daily total fl uid intake (mL) from all beverages, soups, and water-dense foods (i.e., watermelon) was calculated.
Experimental Design
Entering the morning of day 1, subjects had abstained from caffeine for at least 48 h and subsequently consumed about 0 mg caffeine · kg -1 · d -1 in their diets throughout the entire study (13 d total). During a 6-d equilibration phase (days 1 to 6), all subjects consumed a standardized caffeine dose of 3 mg caffeine · kg
via capsules. The experimental design involved three randomized caffeine-dose groups that were stratified for age, body mass, and percent body fat. On days 7 to 11 (treatment phase), each subject consumed a pre-established caffeine dose via capsules of either 0 (C0; placebo; n = 20), 3 (C3; n = 20), or 6 (C6; n = 19) mg caffeine · kg -1 · d -1 . Capsules provided daily group mean (calculated) doses of 0, 226, and 452 mg caffeine/d, respectively. For this purpose, a pharmacist prepared more than 2000 caffeine-containing capsules, the contents of which were certifi ed safe for human consumption. To provide the appropriate caffeine doses specifi c to each subject's body mass, capsules were prepared in 7 denominations ranging from 0 to 200 mg/capsule (relative standard deviation range: 0 to 4.1%).
Capsules were ingested in two equal doses each day, following a doubleblind procedure that was overseen by a nutritional scientist who was not otherwise involved in the study. The morning caffeine dose was ingested between 0700 and 0900 h, in the presence of an investigator; the afternoon dose was taken between 1200 and 1400 h in the presence of an investigator or verifi ed by telephone contact. These caffeine doses represented the only caffeine ingested during this investigation because subjects consumed no caffeine in either food or beverages. Subjects who were assigned to the 0 mg · kg -1 · d -1 group ingested placebo capsules containing powdered lactose.
A blood sample was drawn on days 6 and 11 to assess compliance with the experimental protocol. Because the time to reach peak plasma caffeine concentration is 30 to 60 min, and because this peak concentration (µmol/L) is constant at 60 to 90 min (30, 34) , the caffeine dose was given approximately 1.75 h prior to blood collection. Serum was analyzed for caffeine concentration at the Pennington Biomedical Research Center, Baton Rouge, LA, using high-performance liquid chromatography.
Hydration State and Renal Function
Subjects collected all urine produced (24 h) on days 1, 3, 6, 9, and 12 which was immediately analyzed for 4 variables: urine volume, urine color (5), specifi c gravity using a hand-held refractometer (U sg; model A 300CL, Atago Co., Ltd., Tokyo, Japan) and osmolality via freezing point-depression osmometer (U osm ; mOsm/kg; model 3DII, Advanced Digimatic, Needham Heights, MA). An aliquot of the 24-h sample was stored at -80 °C and subsequently analyzed for Na + and K + (mEq/L) with ion-sensitive electrodes (model 4003, electrolyte analyzer, Medica Corp., Bedford, MA). When multiplied by the urine volume, this concentration provided the total daily electrolyte loss (mEq/24 h). These samples also were analyzed for urine creatinine (procedure #555, Sigma-Aldrich Diagnostics, St. Louis, MO), using a spectrophotometer calibrated at 500 nm (Spectronic 401, Spectronic Instruments, Rochester, NY). Acute urine specimens were collected when subjects returned their 24-h containers on days 1, 3, 6, 9, and 12, and were analyzed for color, U sg , and U osm .
Also on these days, blood was obtained from an antecubital vein while participants were seated. Blood analyses included total plasma protein measured in duplicate with a hand-held refractometer (model A300CL, Atago Corp.) and microhematocrit measured in triplicate following centrifugation for 15 min. After being stored at -80 °C, serum Na + and K + (mEq/L) were measured in duplicate with ion-sensitive electrodes (model 4003, electrolyte analyzer, Medica Corp.). Serum osmolality (mOsm/kg) was measured in an osmometer (model 3DII, Advanced Digimatic). Plasma samples (collected on days 1, 6, 9, and 12) were stored at -80 °C and later analyzed for blood urea nitrogen (Ortho Vitros 950 analyzer, Johnson and Johnson Co., Rochester, NY), with a 1.5% coeffi cient of variation, to evaluate renal function.
Fluid and Electrolyte Balance
Daily Na + and K + excretion (mEq/24 h) were calculated as the product of the urine Na + or K + concentration multiplied by the 24-h urine volume. Whole-body Na + and K + balance were estimated by calculating the arithmetic difference of electrolyte intake minus urinary electrolyte loss (4).
Statistical Analysis
All values were expressed as mean ± standard deviation. Statistical analyses were performed using commercial software (Base 10, SPSS, Inc., Chicago, IL). Subject anthropometric characteristics and caffeine consumption prior to the study were analyzed by analysis of variance (ANOVA). Dietary components were analyzed using a 3 × 11 (group × day) repeated measures ANOVA. All other variables were analyzed using a 3 × 5 (group × day) repeated measures ANOVA. Signifi cance was accepted at P < 0.05. To avoid violating the assumption of independence, means were compared separately across days, using post hoc paired sample t-tests and Holm's sequential Bonferroni correction.
Results
The physical characteristics of subjects in C0, C3, and C6 were found to be statistically similar (P > 0.05). When these groups were combined, the mean (± standard deviation) values for 59 subjects were: age, 21.6 ± 3.3 y; height, 178.1 ± 5.7 cm; body mass, 75.6 ± 7.9 kg; and body-mass index, 23.9 ± 2.41.
The caffeine-use questionnaire described subjects' habitual caffeine consumption prior to entering this study. Because groups C0, C3, and C6 reported similar preinvestigation caffeine intakes (P > 0.05), the data of all subjects were combined to derive a mean daily caffeine intake of 98 ± 17 mg caffeine per day (1.3 mg · kg
). This approximated the caffeine content of one 227 mL (6 oz.) cup of brewed coffee, and was considered to be a low level of intake (6) given that the average adult in the US consumes 3.0 mg · kg
. Cola beverages, chocolate candy, brewed coffee, hot chocolate, iced tea, and chocolate cookies, respectively, were the six most common sources of dietary caffeine, prior to day 1.
The activity questionnaire indicated that subjects exercised an average of 4.1 ± 2.1 sessions per week, for 1.1 ± 0.7 h per session. Using a 3-point scale, subjects rated their usual exercise intensity during workouts as either mild (1), moderate (2), or hard/intense (3), and the mean intensity was 2.2 ± 0.7 (i.e., moderate). A variety of types of exercise (i.e., resistance training, recreational basketball, running, martial arts, cycling, walking) were reported. Based on these fi ndings, subjects were declared to be active but not highly trained. During an exit interview, all subjects stated that they did not alter their exercise program during this investigation.
Dietary macronutrient composition, during consumption of 0 mg caffeine per day in food and beverages, was similar (P > 0.05) for groups C0, C3, and C6. The mean ad libitum values (during a 24-h period, days 1 to 11) for all groups combined were: percent carbohydrate, 52 ± 8%; percent fat, 31 ± 5%; percent protein, 18 ± 4%; sodium intake, 205 ± 53 mEq; potassium intake, 76 ± 25 mEq; and energy intake, 2782 ± 699 Kcal. Figure 1 illustrates the results of serum caffeine analyses (days 6 and 11) performed by high performance liquid chromatography. Serum concentrations for groups C0, C3, and C6 were statistically similar on day 6, but were different (P < 0.05) on day 11 as anticipated. These fi ndings, especially the values for C0 and C6 on day 11, support subject compliance with both the experimental dietary protocol and the consumption of the caffeine capsules twice per day. Table 1 demonstrates that the mean body-mass differences (P < 0.05) occurred within, not between, treatments and that mean total fl uid intake was statistically similar on all days. Similarly, Table 2 demonstrates that minor within-treatment perturbations (P < 0.05, n = 57 and 58) occurred in some analyses of 24-h urine collections (i.e., urine specifi c gravity, urine creatinine excretion, urine Na + excretion, and urine K + excretion); no between-treatment difference was found. Table 3 shows that measurements of acute morning urine samples (n = 58 for all variables; 10 to 20 mL volume per sample) were similar on days 1, 3, 6, 9, and 12, with the exception of day 6 for urine specifi c gravity which was different within f day 9 was different (P < 0.05) from days 1, 3, and 6 within group; g day 9 was different (P < 0.05) from days 1 and 6 within group. treatments C3 and C6. Acute circulatory indices (Table 4) , measured on the same days shown in Table 3 , exhibited minor within-treatment perturbations (P < 0.05) but no between-group differences. The number of samples represented in Table 4 were: hematocrit (n = 59), total plasma protein (n = 37), serum osmolality (n = 59), serum Na + concentration (n = 24), and serum K + concentration (n = 24). The whole-body Na + balance values (days 0, 2, 5, 8, and 11, respectively) were: C0 = 51 ± 136, 84 ± 137, 45 ± 129, 75 ± 101, and 30 ± 93; C3 = 32 ± 141, 35 ± 107, 19 ± 84, 3 ± 120, and 11 ± 127; and C6 = 13 ± 117, 26 ± 76, 56 ± 114, 30 ± 63, and 60 ± 103 mEq/d. The corresponding whole-body K + balance values were (for the same days): C0 = 17 ± 42, 21 ± 31, 31 ± 38, 26 ± 44, and 17 ± 30; C3 = 12 ± 55, 30 ± 35, 37 ± 31, 11 ± 40, and 28 ± 43; and C6 = 18 ± 35, 16 ± 30, 26 ± 55, 15 ± 29, and 18 ± 28 mEq/d. There were no between-group differences (P > 0.05) for either of these variables.
Renal function also was normal as evaluated by urine creatinine excretion (Table 2 ) and blood urea nitrogen. Blood urea nitrogen levels (mg/dl) were measured in all treatment groups as follows (days 1, 6, 9, and 12, respectively): C0 = 16 ± 3, 17 ± 3, 17 ± 3, and 15 ± 3; C3 = 16 ± 3, 17 ± 5, 17 ± 4, and 16 ± 5; and Table 2 C6 = 15 ± 4, 15 ± 4, 17 ± 4, and 16 ± 5. There were no between-group differences (P > 0.05) for this variable.
Discussion
Dieticians, clinicians, and exercise physiologists have recommended that active individuals avoid caffeine because it induces hypohydration, degrades physical performance, or affects health negatively (8, 21, 22, 37) . In contrast to these recommendations, two recent scientifi c review articles (2, 25) concluded that caffeine does not induce chronic hypohydration when consumed in moderation. Although previous studies have assessed the acute effects of caffeine on fl uid-electrolyte balance, the present study was the fi rst laboratory investigation to pose this question during a continuous period longer than 24 h. Healthy males voluntarily participated in 11 d of controlled caffeine consumption and continued their usual weekly recreational and exercise activities. Investigators regularly checked subject compliance with the experimental protocol by verifying ingestion of caffeine capsules (twice per day), measuring serum caffeine concentration (days 6 and 11), reminding subjects of caffeine-containing foods, and reviewing dietary records (each morning). Twenty fl uid-electrolyte, renal, and circulatory variables were measured to 1, 3, 6, 9, and 12 fi ltration and urine formation. But because the central nervous system is complex and numerous neural pathways are sensitive to methylxanthine effects (18) , it would be simplistic to propose that only one caffeine mechanism was involved in the present study. It is clear in the present study, however, that the body's renal and hormonal regulatory responses adequately defended water, Na + , and K + balance, irrespective of the amount of caffeine consumed. In fact, the resting morning plasma arginine vasopressin and serum aldosterone values (not shown), measured on days 6 and 12 of the present study, were similar (P > 0.05) between and within treatments. These data have been published elsewhere (32) .
Thus, the present investigation questions and refi nes the widely-held concept that caffeine acts as a diuretic. Although caffeine could act to increase urine output within hours of consumption, similar to a large bolus of pure water, the key to understanding its physiologic effect involves measuring the percentage of the ingested volume that is chronically retained by the body. A recent review of the scientifi c literature (2) summarized ten previous publications that compared caffeine to water or placebo. Consumption of a caffeinated beverage (100 to 680 mg doses) resulted in 0 to 84% retention of the initial volume of ingested fl uid, whereas consumption of water resulted in a range of 0 to 81% retention. In support of this viewpoint, the present urine volume values (Table 2) show that moderate caffeine doses (3 and 6 mg caffeine · kg -1 · d -1 ) did not increase urine output above that of a placebo (C0). Tables 1 through 4 provide insights regarding changes in caffeine intake. All subjects consumed 3 mg · kg -1 · d -1 during the initial 6 d of the present study, to reduce the infl uence of between-subject differences in habitual caffeine intake on day 1, and to place all subjects in a similar caffeine status. On days 7 to 11, C0 decreased caffeine intake to 0 mg · kg
Change of Caffeine Dose
, the 20 subjects in C3 remained on the equilibration dose, and C6 doubled their daily intake. The variables in Tables 1 through 4 show that such changes of caffeine intake (i.e., C0 and C6 from day 7 to 11) resulted in physiological responses that were similar to C3 (no main group effect; P > 0.05). This indicates that dose changes had no signifi cant infl uence on hydration state.
While it is true that tolerance might develop for some responses to caffeine (i.e., respiratory and cardiovascular effects), it might not occur for all physiological effects (12) . The data in Tables 1 through 4 present no evidence that tolerance developed, not even as a transient response of urine volume, when caffeine levels were modifi ed (C0 and C6) on days 7 through 11. Although these data clarify the widely-held concept of renal tolerance with regard to low and moderate levels of caffeine consumption (C0, C3, C6), they do not exclude the possibility that renal tolerance develops at doses above 6 mg caffeine · kg -1 · d -1
.
Caffeine Effects Within Groups
The aforementioned fi ndings do not mean that within-group changes (across days) were absent. Three examples follow. First, C3 and C6 experienced a small but signifi cant body-mass loss from day 6 to day 9 (0.3 to 0.5 kg; Table 1 ). This loss was subsequently recouped by day 12, however, when the mean body mass was not signifi cantly different from days 1 to 6. A similar phenomenon occurred in the serum Na + concentration (Table 4) of groups C0 and C6, but not C3; the signifi cant increase on day 9 abated by day 12. Second, Na + and K + excretion in 24-h urine collections (Table 2 ) exhibited signifi cant changes (P < 0.05) on specifi c days in C0 and C3, but not in C6. Third, acute urine specifi c gravity and urine color measurements (Table 3 ) fl uctuated in C3 and C6, from day 6 to day 12, but the trends varied. Varying trends also resulted in the signifi cant interaction effects (group × day, P < 0.05) that were detected for urine specifi c gravity (Table 3 ) and total plasma protein ( Table 4) . We view these instances of within-group differences as minor perturbations that occurred by way of the body's defense of water, Na + , and K + homeostasis. Various factors likely infl uenced these within-group changes, including differences in day-to-day dietary content, or differences in spontaneous weekday versus weekend eating patterns (13) . Further, all mean values in Tables 1 through  4 fell within normal clinical ranges (5, 9, 24) and renal function was normal, as determined by blood urea nitrogen and urine creatinine excretion.
In conclusion, the present investigation of healthy, active males provided no evidence to support the notion that active individuals should refrain from consuming moderate levels of caffeine (i.e., C3, 226 mg/d; C6, 452 mg/d). This investigation supports recent literature reviews (2, 25) that found no evidence of a detrimental caffeine-induced fl uid-electrolyte imbalance.
